Research Study

An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma- CheckMate 602: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 602
Principal Investigator 
Kevin Song


Body Locations and Systems 
Blood, Heart and Circulation
Disorders and Conditions 
Multiple Myeloma 
Closed for Recruitment
Study Start/End 
Jun 27, 2017 to Aug 1, 2022
Vancouver General Hospital
Sarah MacEwan, Research Coordinator
604-875-4111 ext 22966
Purpose of Study 

The purpose of this study is to evaluate the safety and effectiveness of several combination therapies for Multiple Myeloma. Upon entry into the study, patients will be randomized (assigned by chance) to receive either:

Group 1: nivolumab, pomalidomide and dexamethasone OR Group 2: pomalidomide and dexamethasone OR Group 3: nivolumab, elotuzumab, pomalidomide and dexamethasone

There is an equal chance to be assigned to either Group 1 or Group 2. There is a lesser chance you will be assigned to Group 3. If you are assigned to receive pomalidomide and dexamethasone only (Group 2) and your disease worsens, you may be eligible to switch to treatment Group 3.


Visit for more information.


Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.